Overview

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and -cell Function in Participants With Type 2 Diabetes Mellitus

Status:
RECRUITING
Trial end date:
2026-12-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of maridebart cafraglutide relative to placebo on insulin sensitivity in participants with Type 2 Diabetes Mellitus (T2DM) treated with stable dose of metformin.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen